From: Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment
Characteristics | All patients, n = 75 | Tumor budding | p | ||
---|---|---|---|---|---|
Low-intermediate, n = 29 | High, n = 46 | ||||
Adjuvant chemotherapy, N (%) | FUFA | 11 (14) | 2 (6) | 9 (19) | 0.2 |
Capecitabine | 8 (10) | 5 (17) | 3 (6) | ||
Folfox | 23 (30) | 8 (28) | 15 (33) | ||
Xelox | 36 (46) | 14 (49) | 19 (42) | ||
Relapse, N (%) | Yes | 41 (55) | 8 (28) | 33 (72) | 0.00 |
No | 34 (45) | 21 (72) | 13 (28) | ||
Relapse pattern, N (%) | Local | 17 (41) | 4 (50) | 13 (39) | 0.9 |
Visceral | 24 (59) | 4 (50) | 20 (61) | ||
KRAS status, N = 41 (%) | Wild | 9 (22) | 3 (38) | 6 (18) | 0.3 |
Mutant | 32 (78) | 5 (62) | 27 (82) | ||
NRAS status, N = 9 (%) | Wild | 8 (89) | 2 (67) | 6 (100) | 0.6 |
Mutant | 1 (11) | 1 (33) | 0 (0) | ||
BRAF status, N = 9(%) | Wild | 8 (89) | 2 (67) | 6 (100) | 0.6 |
Mutant | 1 (11) | 1 (33) | 0 (0) | ||
Disease-free survival | Median (months) | 30 | 43 | 28 | 0.01 |
1 year (%) | 89 | 93 | 86 | ||
3 years (%) | 35 | 61 | 24 |